SPECT study shows effectiveness of brain drug zolpidem

11/10/2009 | Pharmacy Europe

A study in South Africa using SPECT showed that ReGen Therapeutics' zolpidem prevents loss of cognitive and motor functions from brain damage. About half of the study participants given a 10-milligram zolpidem tablet every day experienced sedation, which points to the need for a lower and flexible formulation to improve treatment for each patient, a researcher said.

View Full Article in:

Pharmacy Europe

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN